Cambridge-based therapeutics company Imara has secured $63 million in Series B funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced March 18 and led by Arix Bioscience.
According to its Crunchbase profile, "Imara, Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease, a rare, genetic blood disease that leads to a reduction of healthy red blood cells, blocked blood vessels and a multitude of pathologies. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease."
The four-year-old startup also raised a $31 million Series A round in 2016.
The round brings total funding raised by Cambridge companies in health care over the past month to $245 million. The local health care industry has produced 88 funding rounds over the past year, capturing a total of $2.9 billion in venture funding.
In other local funding news, industrial research company Via Separations announced a $4.8 million Series A funding round on March 14, led by Safar.
According to Crunchbase, "Via Separations develops a materials technology for industrial separation processes that uses 10 times less energy than traditional methods."
The company also raised a seed round in 2017.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
